apricitabine
Small moleculeexperimental
Apricitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI) against HIV. It is structurally related to lamivudine and emtricitabine, and, like these, is an analogue of cytidine. — Wikipedia
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT00126880)
Timeline
Indications
Studied for
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1- Mol. weight
- 229.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaApricitabine ↗
- ChEMBLCHEMBL210651 ↗
Also known as
- apricitabine
- apricitabine
- apricitabine
- apricitabine
- avx754
- avx754
- avx-754
- bch10619
- bch 10619
- bch-10619
- spd754
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00686270 | Phase 3 | May 1, 2008 | Avexa, University of Alabama, Birmingham |
| NCT00612898 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2008 | Avexa, University of Alabama, Birmingham |
| NCT00367952 | Phase 2 | Aug 1, 2006 | Avexa |
| NCT00352066 | Phase 1 | Jul 1, 2006 | Avexa |
| NCT00334659 | Phase 1 | Jun 1, 2006 | Avexa |
| NCT00126880 | Phase 2 | Jul 1, 2005 | Avexa |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avexa | For profit | 6 | 6 | 3 | 2005 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1